• Epigenomics posted a preliminary H1 2026 net loss of EUR 128,000, narrowing from EUR 204,000 a year earlier.
• Revenue more than doubled to EUR 17,000; other operating income climbed to EUR 16,000.
• Cash and bank balances fell to EUR 277,000 at June 30, 2026, from EUR 414,000 at end-2025.
• Negative equity deepened to EUR 11.3 million; the company reiterated its 2026 net result forecast of EUR -0.2 million to EUR -0.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Epigenomics AG published the original content used to generate this news brief via pressetext (Ref. ID: 202607200810PRESSTXTEUPR__DE8A98E8F5FD1B4CC92A939B176789F27) on July 20, 2026, and is solely responsible for the information contained therein.